Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cytovia Raises $45 Million for JV to Develop NK Products in China

publication date: Sep 16, 2021

Cytovia Therapeutics of Florida established a JV in Shanghai with an initial $45 million to develop its “off-the-shelf” CAR products in China. The JV, CytoLynx, will pay up to $400 million in milestones to Cytovia as it develops the parent company's products. Cytovia is developing gene-edited iNK and CAR-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager antibodies. The $45 million initial funding was led by TF Capital and joined by other China venture capital firms. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China